ABSTRACT
Thalassemia is a Mendelian inherited blood disease caused by α- and ß-globin gene mutations, known as one of the major health problems of Mediterranean populations. Here, we examined the distribution of α- and ß-globin gene defects in the Trapani province population. A total of 2,401 individuals from Trapani province were enrolled from January 2007 to December 2021, and routine methodologies were used for detecting the α- and ß-globin genic variants. Appropriate analysis was also performed. Eight mutations in the α globin gene showed the highest frequency in the sample studied; three of these genetic variants represented the 94% of the total α-thalassemia mutations observed, including the -α3.7 deletion (76%), and the tripling of the α gene (12%) and of the α2 point mutation IVS1-5nt (6%). For the ß-globin gene, 12 mutations were detected, six of which constituted 83.4% of the total number of ß-thalassemia defects observed, including codon ß039 (38%), IVS1.6 T > C (15.6%), IVS1.110 G > A (11.8%), IVS1.1 G > A (11%), IVS2.745 C > G (4%), and IVS2.1 G > A (3%). However, the comparison of these frequencies with those detected in the population of other Sicilian provinces did not demonstrate significant differences, but it contrarily revealed a similitude. The data presented in this retrospective study help provide a picture of the prevalence of defects on the α and ß-globin genes in the province of Trapani. The identification of mutations in globin genes in a population is required for carrier screening and for an accurate prenatal diagnosis. It is important and necessary to continue promoting public awareness campaigns and screening programs.
Subject(s)
COVID-19 , alpha-Thalassemia , beta-Thalassemia , Female , Humans , Pregnancy , alpha-Globins/genetics , beta-Globins/genetics , beta-Thalassemia/epidemiology , beta-Thalassemia/genetics , COVID-19/epidemiology , Genotype , Mutation , Prevalence , Retrospective Studies , alpha-Thalassemia/epidemiology , Sicily/epidemiologySubject(s)
COVID-19/epidemiology , Pandemics , SARS-CoV-2 , beta-Thalassemia/epidemiology , Activin Receptors, Type II/therapeutic use , Adult , Asymptomatic Infections , COVID-19/complications , Cardiovascular Diseases/etiology , Chelation Therapy/adverse effects , Clinical Trials as Topic , Comorbidity , Dietary Supplements , Female , Hospitalization/statistics & numerical data , Humans , Immunocompromised Host , Immunoglobulin Fc Fragments/therapeutic use , Iron Chelating Agents/adverse effects , Iron Chelating Agents/therapeutic use , Iron Overload/epidemiology , Iron Overload/etiology , Lebanon/epidemiology , Male , Obesity/epidemiology , Phosphodiesterase Inhibitors/therapeutic use , Prevalence , Recombinant Fusion Proteins/therapeutic use , Severity of Illness Index , Splenectomy , Tertiary Care Centers , Vitamins , beta-Thalassemia/complications , beta-Thalassemia/drug therapy , beta-Thalassemia/immunologySubject(s)
Antiviral Agents/pharmacology , Boron/pharmacology , Curcumin/pharmacology , SARS-CoV-2/drug effects , Antiviral Agents/administration & dosage , Boron/administration & dosage , Boron Compounds/administration & dosage , Boron Compounds/pharmacology , COVID-19/blood , COVID-19/epidemiology , COVID-19/virology , Curcumin/administration & dosage , Drug Synergism , Gene Frequency , Hemin/pharmacology , Heterozygote , Humans , Iron/blood , Oxidative Stress/drug effects , Phytotherapy/methods , SARS-CoV-2/physiology , beta-Thalassemia/blood , beta-Thalassemia/epidemiology , beta-Thalassemia/genetics , COVID-19 Drug TreatmentSubject(s)
Betacoronavirus , Coronavirus Infections/epidemiology , Pneumonia, Viral/epidemiology , beta-Thalassemia/epidemiology , Adult , COVID-19 , Comorbidity , Female , Humans , Italy/epidemiology , Male , Middle Aged , Pandemics , Preliminary Data , SARS-CoV-2Subject(s)
Blood Transfusion/statistics & numerical data , COVID-19/epidemiology , SARS-CoV-2 , beta-Thalassemia/epidemiology , Afghanistan/epidemiology , Blood Donors/supply & distribution , COVID-19/economics , COVID-19/prevention & control , Comorbidity , Culturally Competent Care , Deferoxamine/supply & distribution , Deferoxamine/therapeutic use , Female , Health Services/supply & distribution , Health Services Needs and Demand , Humans , Literacy , Male , Secondary Prevention , Social Determinants of Health , Transfusion Reaction/prevention & control , Unemployment , beta-Thalassemia/drug therapy , beta-Thalassemia/economics , beta-Thalassemia/therapyABSTRACT
During the coronavirus-19 disease (COVID-19) pandemic, several studies were performed to determine the mortality and incidence rates of coronavirus infection among patients with hemoglobinopathies. However, there has been no systematic approach or meta-analysis to evaluate the results worldwide. This meta-analysis summarized the existing evidence of incidence and mortality rates of COVID-19 and related risk factors among patients with hemoglobinopathies with a focus on ß-thalassemia (ß-thal) and sickle cell disease. The review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses checklist. Two authors independently screened the articles, extracted eligible ones, and assessed the quality of studies using the Joanna Briggs Institute (JBI) checklist. The collected data were analyzed by the Stata software. The amount of heterogeneity was demonstrated by the I2 test. The incidence of COVID-19 among patients with a hemoglobinopathy, ß-thal and sickle cell disease was 4.44, 1.34, and 17.22 per 100,000 person-day, respectively, to June 15 2020. The mortality rate of COVID-19 in patients with hemoglobin (Hb) disorders was calculated as 1.07 per 1000 person-day in the same period. Our findings showed a higher incidence rate of COVID-19 in sickle cell disease patients compared to the general population. A slightly higher mortality rate was also observed in patients with hemoglobinopathies compared to the general population, possibly due to the associated risk factors and comorbidities in this vulnerable group, which underscore special care, timely diagnosis and management along with current immunization, were crucial in decreasing the frequency, disease severity and mortality of these patients.
Subject(s)
Anemia, Sickle Cell , COVID-19 , Hemoglobinopathies , beta-Thalassemia , Anemia, Sickle Cell/complications , Anemia, Sickle Cell/epidemiology , COVID-19/epidemiology , Hemoglobinopathies/epidemiology , Humans , Incidence , beta-Thalassemia/epidemiologyABSTRACT
OBJECTIVES: With the advent of COVID-19 in Pakistan, the already fragmented blood transfusion services (BTS) received a severe blow, putting the lives of transfusion-dependent thalassemia children on stake. This study aimed to assess the impact of the COVID-19 on blood transfusion therapy (BTT) of thalassemia patients and suggest ways to ensure safe and reliable blood supplies amid such health crises. MATERIAL AND METHODS: A retrospective, cross-sectional study was conducted from October 2019 (before COVID-19) to July 2020 (during COVID-19) based on the data provided by a thalassemia center, named Help International Welfare Trust, Karachi, Pakistan. SPSS version 24.0 was used for the data analysis. Data were described in the form of means and percentages. RESULTS: There was a significant reduction in the consumption of PRBCs bags after the emergence of COVID-19 (P=0.002). Moreover, the number of thalassemia patients receiving BTT was dropped by 10.56% during the pandemic. There was a strong negative correlation observed between the rising cases of COVID-19 in Pakistan and the number of patients missing their therapy sessions (r=-0.914, P=0.030). A considerable decline in the reserves of all Rhesus-negative blood groups amid the COVID-19 outbreak was also observed. CONCLUSION: The COVID-19 pandemic adversely affected the already suboptimal care catered to thalassemia patients in Karachi, Pakistan. The fear of the virus contraction coupled with the lockdown and restricted mobility has disrupted the entire transfusion chain from donor to the recipient. Collaborated efforts by the government and healthcare authorities are essential to ensure sufficient blood for thalassemia patients amid the pandemic.
Subject(s)
Blood Donors/supply & distribution , Blood Transfusion/statistics & numerical data , COVID-19 , Continuity of Patient Care , Pandemics , SARS-CoV-2 , beta-Thalassemia/therapy , Adolescent , Blood Grouping and Crossmatching , Child , Child, Preschool , Cross-Sectional Studies , Female , Health Services Accessibility , Humans , Male , Pakistan/epidemiology , Patient Acceptance of Health Care , Patient Compliance , Procedures and Techniques Utilization , Retrospective Studies , Rural Population , beta-Thalassemia/epidemiologyABSTRACT
ß-Thalassemia (ß-thal) is one of the most common inherited diseases all over the world. These patients are very susceptible to infection disease, and the mortality and morbidity of infected patients will increase. The object of this systematic review study was to determine mortality and morbidity of infected ß-thal patients with coronavirus disease 2019 (COVID-19). We searched PubMed, Elsevier, and Scholar Google to obtain related papers. The time of search was 21 June until 17 July 2020. All original and review articles and case reports were searched with key words: COVID 19, beta or ß-thalassemia (ß-thal), mortality and morbidity. Data were extracted after quality assessment of all articles. We obtained seven, 21 and six articles from PubMed, Scholar Google and Science Direct, respectively. Finally, seven articles were discussed in our study. The total number of enrolled patients was 34. Twenty-six patients carried transfusion-dependent ß-thal major (ß-TM). The most common symptoms were fever, cough, pain and dyspnea. Nine patients died. The result of this study has shown that the mortality and morbidity of infected ß-thal patients will escalate.
Subject(s)
COVID-19/epidemiology , Pandemics , SARS-CoV-2 , beta-Thalassemia/epidemiology , Adolescent , Adult , Aged , Aged, 80 and over , Anticoagulants/therapeutic use , COVID-19/mortality , Comorbidity , Diabetes Mellitus/epidemiology , Female , Global Health , Hospitalization/statistics & numerical data , Humans , Hypertension, Pulmonary/epidemiology , Immunocompromised Host , Male , Middle Aged , Splenectomy/adverse effects , Thrombophilia/drug therapy , Thrombophilia/etiology , Young Adult , beta-Thalassemia/mortality , beta-Thalassemia/surgeryABSTRACT
BACKGROUND: Coronavirus disease 2019 (COVID-19) outbreak is a global and challenging disease that is accompany with mortality and morbidity. AIM OF STUDY: We evaluated the prevalence and the impact of comorbidities in thalassemia Iranian patients affected by COVID-19. Methods: A multicenter, retrospective, cross-sectional study was conducted across all comprehensive thalassemia centers in Iran, from January to June 15th, 2020. RESULTS: Forty-three confirmed COVID-19 thalassemia patients (32 TDT, and 11 NTDT) were detected. The mean age of patients was 35.3 ± 11.5 years (range 9 - 67); 21 females and 22 males. Overall, 78.1% of TDT and 90.9% of NTDT patients were complicated with at least one comorbidity (P: 0.656). The overall mortality rate of thalassemia patients with COVID-19 was 18.6% while 27.3% was in NTDT patients compared to 15.6% in TDT patients (P:0.401). The dead group had a non-significant higher frequency of endocrinopathies compared to the recovered group (62.5% versus 45.7% P:0.457). Ten female thalassemia patients with positive COVID-19 had hypogonadism, six patients were receiving hormone replacement therapy and all of them recovered (zero death) compared to two deaths from 4 patients who were not receiving hormone replacement therapy (P:0.133). Furthermore, the prevalence of COVID-19 in NTDT patients was significantly higher than the general population (45 per 10,000 versus 22.29 per 10,000 respectively, P:0.018) while the prevalence of TDT was almost similar to the normal population (P:0.539). The mortality rate of COVID-19 was 4.71% in the normal Iranian population compared to 18.6% in ß-thalassemias (P: <0.001) at the same date. CONCLUSIONS: It is important to acknowledge that ß-thalassemia patients, especially young adults/adults, have a chronic condition which may contribute to increase susceptibility to SARS-CoV-2 infection. A higher susceptibility to the infection was observed in patients with NTDT and in untreated hypogonadal female thalassemic patients. However, to confirm these data, more accurate designed studies are needed.
Subject(s)
Betacoronavirus , Blood Transfusion , Coronavirus Infections/epidemiology , Disease Transmission, Infectious/prevention & control , Pneumonia, Viral/epidemiology , Population Surveillance , beta-Thalassemia/epidemiology , Adolescent , Adult , Aged , COVID-19 , Child , Comorbidity , Coronavirus Infections/transmission , Cross-Sectional Studies , Female , Humans , Iran/epidemiology , Male , Middle Aged , Pandemics , Pneumonia, Viral/transmission , Prevalence , Prognosis , Retrospective Studies , SARS-CoV-2 , Survival Rate/trends , Young Adult , beta-Thalassemia/therapySubject(s)
Betacoronavirus , Coronavirus Infections/epidemiology , Pneumonia, Viral/epidemiology , beta-Thalassemia/epidemiology , Adult , Aged , COVID-19 , Comorbidity , Cross-Sectional Studies , Female , Humans , Iran/epidemiology , Male , Middle Aged , Pandemics , Prevalence , Prognosis , Retrospective Studies , SARS-CoV-2 , Severity of Illness Index , Young AdultSubject(s)
Coronavirus Infections/prevention & control , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , beta-Thalassemia/epidemiology , Betacoronavirus , COVID-19 , Coronavirus Infections/epidemiology , Disease Resistance , Geography , Hemoglobins/chemistry , Heterozygote , Humans , Italy/epidemiology , Open Reading Frames , Pneumonia, Viral/epidemiology , Porphyrins/chemistry , Prevalence , SARS-CoV-2ABSTRACT
The novel coronavirus pneumonia (COVID-19) is a contagious acute respiratory infectious disease whose causative agent has been demonstrated to be a novel virus of the coronavirus family, SARSCoV-2. A recent PRE-print study has showed a heme attack on the 1-beta chain of hemoglobin by COVID19. Beta-thalassemia results of a default in the hemoglobin beta-chain synthesis. 1,5% global population are heterozygotes for this disease. In this study, by a multiple linear regression, we have analyzed the evolution of COVID-19 infection in three Italian regions (Puglia, Sardinia, Sicilia) with different beta-thalassemic prevalences, in order to search a link. The results have showed that betathalassemic heterozygote population prevalence is correlated to immunity against COVID-19, by a regression. This paper is only for academic discussion, the hypotheses and conclusions needs to be confirmed by further research.